CD52 (ALLO-647 Biosimilar) Recombinant Monoclonal Antibody

1. soluble CD52 exerts a concerted immunosuppressive effect by first sequestering HMGB1 to nullify its proinflammatory Box B, followed by binding to the inhibitory Siglec-10 receptor, triggering recruitment of SHP1 to the intracellular immunoreceptor tyrosine-based inhibitory motif of Siglec-10 and its interaction with the TCR. PMID: 29997173
2. CD52 is a novel prognostic NSC marker and a potential NSC target in a subset of patients with MDS and AML, which may have clinical implications and may explain clinical effects produced by alemtuzumab in these patients. PMID: 24799522
3. carbohydrate moiety of sperm protein interferes with the complement system via binding to C1q PMID: 22386526
4. CT60 single-nucleotide polymorphism of CTLA4 is a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia PMID: 21552305
5. Clonal large granular lymphocytes exhibited decreased CD52 expression post-therapy in patients refractory to treatment. PMID: 19794084
6. Our bioinformatics findings suggest that CD52 polymorphism may affect the efficiency of GPI anchor formation and thus may indirectly alter the response to anti-CD52 agents like alemtuzumabin renal transplantation. PMID: 20349607
7. Review article on CD52 structure and function. PMID: 11860230
8. HE5(CD52) mRNA and protein, expressed in epithelial cells of the distal epididymis, were not affected by the obstruction of the vas deferens. PMID: 14662784
9. The relationship between this differential insertion and differences in glycosylation of rat and human CD52 is discussed. PMID: 16266689
10. CD52 is widely expressed on human mast cells (MCs) and Waldenstrom's Macroglobulinemia bone marrow lymphoplasmacytic cells and provide the preclinical rationale for the use of alemtuzumab in the treatment of WM and possibly other MC-related disorders. PMID: 16796779
11. In this study, we identified the antigen of 4C8 mAb as CD52. CD52 is a costimulatory molecule for induction of CD4-positive T cells. PMID: 16797237
12. In contrast with CLL, the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy. PMID: 17145843
13. Our data demonstrate differences in the intensity of the CD52 antigen expression between B-lymphocytes and tumor lymphocytes of B-CLL patients, and between B-CLL and SLL tumor cells. CD52 antigen is expressed at low level on CD34(+) cells. PMID: 17428002
14. The semenogelin-CD52 soluble form is a direct consequence of the liquefaction process in human semen. PMID: 17624925
15. We first showed the expression of CD52 in human cumulus cells. CD52 has some functional roles around fertilization in females as well as in males. PMID: 18647288
16. A review on CD52 expression and function PMID: 11257744

Show More

Hide All

HGNC: 1804

OMIM: 114280

KEGG: hsa:1043

STRING: 9606.ENSP00000363330

UniGene: Hs.276770